Letrozole Teva

Letrozole, the active ingredient in Letrozole Teva, is a aromatase inhibitor presented as an oral tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozole Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole is an aromatase inhibitor used in the management of hormone‑dependent breast cancer.

Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen production to inhibit tumor growth. Adjuvant treatment of early‑stage breast cancer: helps prevent recurrence after surgery. Metastatic breast cancer: slows disease progression by limiting estrogen‑driven tumor growth.

Letrozole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Severe liver injury - Osteoporotic fractures - Deep vein thrombosis or pulmonary embolism - Severe allergic reactions (anaphylaxis) - Cardiac arrhythmias (QT prolongation) - Hypercholesterolemia

Before initiating Letrozole therapy, clinicians should consider several safety measures.

Monitor bone density: assess risk of osteoporosis and consider supplementation. Assess liver function: perform baseline and periodic liver enzyme tests. Evaluate cardiovascular risk: watch for thromboembolic events. Review concomitant medications: avoid drugs that may interact with aromatase inhibition. Counsel on menopausal symptoms: discuss management of hot flashes and fatigue. Store at below 25°C: keep in the original pack, protect from moisture.

Letrozole can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) may reduce efficacy. - Tamoxifen may antagonize aromatase inhibition. - Estrogen replacement therapy can counteract therapeutic effect.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole) may increase plasma levels. - Anticoagulants (e.g., warfarin) may require dose adjustment. - Selective serotonin reuptake inhibitors (SSRIs) may affect metabolism.